8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT
                       PURSUANT TO SECTION 13 OR 15(D) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

         Date of Report (Date of earliest event reported): March 5, 2007

                         Renhuang Pharmaceuticals, Inc.
             (Exact name of registrant as specified in its charter)

                                     Nevada
                 (State or Other Jurisdiction of Incorporation)


                  0-24512                          88-1273503
          (Commission File Number)    (IRS Employer Identification Number)

                    No. 281, Taiping Road, Taiping District,
                      Harbin, Heilongjiang Province, 150050
                                   P. R. China
                    (Address of Principal Executive Offices)

                                +86-451-5762-0378
              (Registrant's Telephone Number, Including Area Code)


Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_| Written communications pursuant to Rule 425 under the Securities Act
    (17 CFR 230.425)

|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act
    (17 CFR 240.14a-12)

|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
    Act (17 CFR 240.14d-2(b))

|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
    Act (17 CFR 240.13e-4(c))


- --------------------------------------------------------------------------------








Item 7.01   Regulation FD Disclosure.
            -------------------------

 On March 5, 2007, Renhuang Pharmaceuticals, Inc (the "Company") issued a press
release, a copy of which is attached as Exhibit 99.1 to this report and is being
furnished to the SEC and shall not be deemed "filed" for any purpose.



Item 9.01   Financial Statements, Pro Form Financial Information and Exhibits.
(c)         Exhibits.


                                    EXHIBITS

Exhibit                           Description
- -------                           ----------------------------------------------
99.1                              Press Release dated March 5, 2007.


- --------------------------------------------------------------------------------










                                    SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                    Renhuang Pharmaceuticals, Inc.


Date: March 5, 2007                 By: /s/ Shaoming Li
                                        ----------------------------------------
                                        Shaoming Li
                                        Chief Executive Officer and President


- --------------------------------------------------------------------------------

EX-99.1

                                                                    Exhibit 99.1

            Renhuang Pharmaceuticals Completes Acquisition
                of Herbal Medicine Extraction Company

                  Doubles Herbal Extracting Capacity
                 and Reduces Overall Production Cost


    HARBIN, China--(BUSINESS WIRE)--March 5, 2007--Renhuang
Pharmaceuticals, Inc. (or "the Company", Stock symbol: RHGP.OB), a
leading provider of natural health care products in the People's
Republic of China (PRC), today announced it completed the transaction
to acquire the Qingyang Herbal Extracting Factory from Yerui
Pharmaceutical Co. Ltd. On February 26, 2007, the Company announced
the signing of the letter of intent for this acquisition. The Qingyang
Herbal Extracting Factory, located in Yanshou Township, Harbin, China,
is a manufacturing facility that processes raw herbal plants into
extracts - the intermediate material for Chinese herbal medicine
finished products. This acquisition is consistent with Renhuang's
strategy of expanding its herbal extracting capabilities, which will
position the Company well for further growth.

    The acquired facility is capable of processing approximately
18,000 tons of herbal raw materials into extracts, doubling the
Company's current herbal extraction capacity. The factory is located
in proximity of herbal planting farms, allowing easy access to herbal
raw materials, including Acanthopanax for making Siberian Ginseng
derived products, Isatis for making Ban Lan Gen, and Schisandra
chinensis for making other traditional herbal medicines.

    Mr. Li, Shaoming, chairman and chief executive officer of
Renhuang, commented on the acquisition, "Under the current government
policies that encourage consolidation activities in the pharmaceutical
industry in China, acquiring an existing and operationally experienced
factory is far less costly and far more expeditious than building a
new factory. This acquisition allows us to expand our herbal
extraction capabilities quickly with substantially less investments to
cope with the fast growth in our business. The addition of the
Qingyang Herbal Extracting Factory is also expected to significantly
lower our overall production cost by providing better integration
between our raw material processing and finished products
manufacturing as well as other operating synergies."

    Renhuang Pharmaceuticals will immediately begin the process of
integrating the newly acquired extraction factory into its existing
manufacturing facility. The Company will introduce its best practices
and technologies to the new facility and consider additional
investments to upgrade or replace machinery and equipment in order to
improve efficiency and reduce operating costs. Given that this is an
asset-only acquisition, approximately 100 staff including management
personnel, technical personnel, and factory workers will need to be
hired gradually and trained to operate the facility in order to bring
the factory to full production.

    "Our management team has a proven track record in successfully
identifying and executing cost efficient acquisitions. One example is
Dongfanghong Pharmaceutical Co. (DFH) that the Company acquired in
2003 from the local government for approximately $800,000. DFH
controls 70% of all wild Acanthopanax resources in China and also owns
an herbal extraction plant that processes raw Acanthopanax. One year
after the acquisition in 2004, we were able to generate $3.75 million
in revenues from the sales of Acanthopanax-based products by utilizing
DFH's production capabilities. In fiscal year 2006 from November 1,
2005 to October 31, 2006, the plant generated $16.1 million in
revenue, a 329% increase over the previous year. The Acanthopanax
derived products from the DFH plant have become the core product line
of Renhuang - a major contributor to the Company's total earnings and
representing more than 50% of total annual revenues," Mr. Li, Shaoming
noted.

    Under the terms of the agreement, Renhuang acquired the facility
for RMB 3,735,000 in cash (approximately USD $500,000) including
assumed bank loan and interest of RMB 1,320,000. The Company has
already made a cash payment of RMB 2,415,000 to the seller. The RMB
1,320,000 bank loan and interest are expected to be repaid directly to
the bank within 3 months and the Company is negotiating with the bank
to that effect.

    Mr. Li continued, "We have been looking for opportunities to
expand our extraction capabilities in order to build a solid
foundation to become the largest manufacturing, R&D, and supply base,
providing standardized extracts and ingredients for our own various
herbal nutraceuticals and natural medicinal products as well as for
other third-party manufacturers. Given its convenient location that
suits our long-term growth strategy, the Qingyang Herbal Extracting
Factory came to our attention and we were able to acquire it at what
we consider an attractive price. Based on our successful acquisition
experience, we believe the new assets will significantly contribute to
the profitable growth of our business."

    About Renhuang Pharmaceuticals, Inc.:

    Renhuang Pharmaceuticals is a leading bio-pharmaceutical company
located in Harbin in the Heilongjiang Province in Northeast China.
Renhuang is primarily engaged in the research, production, and sales
of bio-pharmaceutical products in Mainland China. The Company's main
products are Siberian ginseng, shark liver oil and several other
traditional medical products. It is estimated that 70% of China's
natural supply of Siberian Ginseng is currently controlled by the
Company.

    The company also anticipates approval within six to nine months by
State Food and Drug Administration ("SFDA") for up to five of its new
Monoclonal Antibody Reagent Box series products. These products are
60% more reliable than those from its competitors and also adhere to
"Good Manufacturing Practices", or "GMP". Moreover, the company is in
the process of building its own immune system research and development
function. Overall, the company is able to achieve significant cost
savings compared to most of its competitors, who purchase their raw
materials from third parties.

    Over 2000 sales agents are employed in seventy sales centers
across twenty-four districts and cover over 50% of the greater China
area and 80% of its population, including the most populous and
developed Eastern China. The Company employs over 50 people in its R&D
department, a number of which are well recognized and respected
pharmaceutical professors and research scientists from National Navy
Pharmaceutical Research Center, Beijing Ellionbio Research Center and
other well known institutions. State of the art research and
production facilities using the latest technologies are currently used
by the Company's scientists to develop new and innovative areas,
including antiseptic and immune system products and Diagnostic kits.
RHGP-G

    Safe Harbor Statement

    This press release contains certain statements that may include
'forward-looking statements' as defined in the Securities Act of 1933,
and the Securities Exchange Act of 1934. All statements, other than
statements of historical facts, included herein are 'forward-looking
statements.' Although the Company believes that the expectations
reflected in these forward-looking statements are reasonable, they do
involve assumptions, risks and uncertainties, and these expectations
may prove to be incorrect. You should not place undue reliance on
these forward-looking statements, which speak only as of the date of
this press release.

    The Company's actual results could differ materially from those
anticipated in these forward-looking statements as a result of a
variety of factors, including those discussed in the Company's
periodic reports that are filed with and available from the Securities
and Exchange Commission. All forward-looking statements attributable
to the Company or persons acting on its behalf are expressly qualified
in their entirety by these factors. Other than as required under the
securities laws, the Company does not assume a duty to update these
forward-looking statements.


    CONTACT: Christensen
             Christy Shue, 917-576-2209
             cshue@ChristensenIR.com
             or
             In China:
             Renhuang Pharmaceuticals Inc
             Gina Gao, 0086-451-57620378
             Fax: 0086-451-57606414
             gs@renhuang.com